Onconetix, Inc. (NASDAQ:ONCO) Stock Short Interest Report for October

Onconetix, Inc. (NASDAQ:ONCO) was the recipient of a significant growth in short interest during the month of October. As of October 30th, there was short interest totaling 957,609 shares, a growth of 145.6% from the October 15th total of 389,871 shares. Based on an average trading volume of 5,373,971 shares, the days-to-cover ratio is presently 0.2 days. Currently, 163.1% of the company’s shares are short sold.

Onconetix Price Performance

ONCO stock traded up $0.04 during midday trading on Friday, reaching $3.08. 29,140 shares of the company’s stock traded hands, compared to its average volume of 168,222. Onconetix has a fifty-two week low of $2.91 and a fifty-two week high of $1,610.00. The business has a 50-day moving average price of $6.32 and a two-hundred day moving average price of $113.93. The company has a market capitalization of $1.81 million, a P/E ratio of 0.00 and a beta of 2.62.

Onconetix (NASDAQ:ONCO) last released its quarterly earnings data on Thursday, August 13th. The company reported ($12.80) earnings per share (EPS) for the quarter, topping the consensus estimate of ($45,050.00) by $45,037.20. Onconetix had a negative net margin of 1,575.89% and a negative return on equity of 91.95%. The company had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.02 million.

Wall Street Analyst Weigh In

Several equities research analysts have commented on ONCO shares. Weiss Ratings upgraded Onconetix from a “sell (e)” rating to a “sell (e+)” rating in a research note on Thursday, October 29th. Wall Street Zen upgraded Onconetix from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. One research analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Onconetix Company Profile

Onconetix, Inc. is a biotechnology company focused on developing and commercializing diagnostic and therapeutic products for men’s health. The company’s portfolio is centered primarily on prostate health, with products intended to support the detection, risk assessment and treatment of prostate-related conditions. Its lead diagnostic product is Proclarix, a blood-based test designed to help assess the risk of clinically significant prostate cancer in men with elevated prostate-specific antigen (PSA) levels.